Raptor’s mission is to research, produce, and deliver medicines that improve life for patients with severe, rare diseases.

 

Raptor Applies for Marketing Approval of RP103 for the Potential Treatment of Nephropathic Cystinosis in the U.S. and E.U.

In March 2012, Raptor received validation of its Marketing Authorization Application from the European Medicines Agency for RP103 cysteamine bitartrate delayed-release capsules (DR Cysteamine) for the potential treatment of nephropathic cystinosis. Raptor also submitted its New Drug Application with the U.S. Food and Drug Administration.